The publication of the PRONTO-T2D-3 trial results in The Lancet in January 2026 — demonstrating that insulin pump therapy in severely insulin-resistant Type 2 diabetes patients requiring more than 100 units of daily insulin reduces HbA1c by an average of 1.9 percentage points more than optimized multiple daily injection therapy over 12 months — has catalyzed a reassessment of pump...
Italiano 
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Tiếng Việt